Why Revolution Medicines May Be Big Pharma’s Next Takeover Target
Quick Read RVMD has surged 492% over one year on daraxonrasib’s landmark pancreatic cancer data showing 13.2 versus…
Global drug makers face pricing pressure as China targets affordable healthcare
Global pharmaceutical companies posted mixed earnings in China last year, with some firms warning that 2026 will be…
Some Georgians could soon be paying double for their medications – WSB-TV Channel 2
ATLANTA — In just a matter of days, President Donald Trump’s pharmaceutical tariff policy will go into effect,…
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company’s biggest revenue…